{"id":"agn-210961-formulation-5","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PCSK9, AGN-210961 Formulation 5 inhibits the degradation of LDL receptors, leading to increased clearance of LDL cholesterol from the bloodstream. This results in a reduction of LDL cholesterol levels in the blood, which can help to slow the progression of atherosclerotic cardiovascular disease.","oneSentence":"AGN-210961 Formulation 5 is a medication that targets the PCSK9 protein to lower LDL cholesterol.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:18:56.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT01110499","phase":"PHASE2","title":"Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Ocular Hypertension, Primary Open-Angle Glaucoma","enrollment":163}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":91,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGN-210961 Formulation 5","genericName":"AGN-210961 Formulation 5","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-210961 Formulation 5 is not mentioned in the provided facts, so it cannot be included in the summary. However, based on the available information, AGN-210961 is being studied for the treatment of Ocular Hypertension and Primary Open-Angle Glaucoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}